702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial

BACKGROUND: Live biotherapeutic products (LBPs) are adjunctive therapies to prevent recurrence of Clostridioides difficile infection (CDI). In this post hoc subgroup analysis, the durability of fecal microbiota, live-jslm (REBYOTA™; abbreviated here as RBL, previously known as RBX2660), the first mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Reveles, Kelly R, Gonzales-Luna, Anne J, Golan, Yoav, Alonso, Carolyn D, Guthmueller, Beth, Tan, Xing, Bidell, Monique, Pokhilko, Victoria, Crawford, Carl, Skinner, Andrew M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678640/
http://dx.doi.org/10.1093/ofid/ofad500.764

Ejemplares similares

Ejemplares similares